VistaGen Therapeutics, Inc.
VTGN
$3.16
$0.10443.41%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -68.05% | -75.12% | -47.51% | -11.52% | 28.43% |
Total Depreciation and Amortization | 12.59% | 11.80% | 10.22% | 9.10% | 7.07% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 29.67% | 79.43% | -37.83% | -48.71% | -58.09% |
Change in Net Operating Assets | 38.93% | 500.25% | 760.63% | 186.57% | 144.38% |
Cash from Operations | -73.92% | -63.08% | -48.36% | -6.35% | 30.86% |
Capital Expenditure | -107.77% | -213.11% | -312.50% | -1,212.00% | -179.13% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -52.17% | -- | -- | -- | -- |
Cash from Investing | -53.20% | -21,454.10% | -2,347.14% | -2,363.27% | -878.58% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 88.52% | -- | 100.00% | 100.06% | 30.79% |
Issuance of Common Stock | -97.17% | -97.53% | -99.03% | 1,180,363.64% | 843,088.31% |
Repurchase of Common Stock | -- | -- | -75,900.00% | -75,900.00% | -75,900.00% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -200.23% | -211.97% |
Cash from Financing | -96.39% | -97.50% | -99.32% | 172.02% | 79,610.90% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -157.81% | -150.75% | -151.07% | 1,909.31% | 320.22% |